Attenta is a medicine containing the active ingredient(s) methylphenidate. On this page you will find out more about Attenta, including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.
Active ingredient in this medicine: methylphenidate
Information for medicine and pack size:
Attenta 10 mg uncoated tablet, 100
Consumer Medicine Information leaflet:
No consumer medicine information leaflet was found for the pack size you selected. It may be unavailable or there may be a technical problem. You should speak to your pharmacist, healthcare professional, or call healthdirect on 1800 022 222 for more information.
What this medicine is for
Attention deficit hyperactivity disorder (ADHD). ADHD was previously known as attention deficit disorder. Other terms being used to describe this behavioural syndrome include minimal brain dysfunction in children, hyperkinetic child syndrome, minimal brain damage, minimal cerebral dysfunction, minor cerebral dysfunction, and psycho-organic syndrome of children. Attenta is indicated as part of a comprehensive treatment program which typically includes other remedial measures (psychological, educational, social) for achieving a beneficial effect in children with a behavioural syndrome characterised by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity (not always present) and impulsivity. The diagnosis of this syndrome should not be made when these symptoms are only of recent origin. Non-localising (soft) neurological signs, emotional lability, learning disability and an abnormal electroencephalogram (EEG) may or may not be present, and a diagnosis of CNS dysfunction may or may not be warranted. Special diagnostic considerations for ADHD. The aetiology of this syndrome is unknown, and there is no single diagnostic test. Adequate diagnosis requires the use not only of medical but also of psychological, educational and social resources. Characteristics commonly reported include chronic history or short attention span, distractibility, emotional lability, impulsivity, moderate to severe hyperactivity, minor neurological signs and an abnormal EEG. Learning may or may not be impaired. The diagnosis must be based upon a complete history and evaluation of the child and not solely on the presence of one or more of these characteristics. Drug treatment is not indicated for all children with this syndrome. Stimulants are not intended for use in children who exhibit symptoms secondary to environmental factors (eg. child abuse in particular) or primary psychiatric disorders. Appropriate educational placement is essential and psychosocial intervention is generally necessary. When remedial measures alone are insufficient, the decision to prescribe stimulant medication will depend upon the doctor's assessment of the chronicity and severity of the child's symptoms. Narcolepsy. The symptoms include daytime sleepiness, inappropriate sleep episodes and rapidly occurring loss of voluntary muscle tone. Effective for symptoms of sleepiness but not for loss of voluntary muscle tone.
Table of characteristics
|Visual appearance||7mm white flat bevel edged tablet, debossed with "MP" and "10" either side of a central breakline on one side, and "Greek Alpha Symbol" on the reverse.|
|Dosage Form||Tablet, uncoated|
|Route of administration||Oral|
100 tablets: Controlled Drug
There is one type of pack available.
Pack type 1
|Storage temperature||Store below 25 degrees Celsius|
|Storage conditions||No information available|
|Life time||18 Months|
We were unable to verify that this medicine is available on the PBS (Pharmaceutical Benefits Scheme). Please consult your pharmacist if you need further information
The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.
Is this medication banned in sport?
Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.